Journals / Bozok Veterinary Sciences / 2022 / Cilt: 3 - Sayı: 1

Extendend Spectrum Beta-Lactamase with Carbapenem and Colsitin Resistance on Enterobacteriaceae Strains

Enterobacteriaceae Suşlarında Genişlemiş Spektrumlu Beta-laktamaz ile Karbapenem ve Kolistin Direnci

Pages
12–19
Publication Date
2022-06-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this study is to reveal the importance of ESBL, carbapenems, and colistin antibiotic groups and the resistance developing against these antibiotic groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Recently, antibiotic resistance has become an important risk threatening human and animal health.
📊
Key Findings & Data:Multiple antibiotic drug resistance is frequently reported by researchers.
💡
Conclusion & Impact:The aim of this study is to reveal the importance of ESBL, carbapenems, and colistin antibiotic groups and the resistance developing against these antibiotic groups.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Genişlemiş spektrumlu Beta-laktamaz · Karbapenem · Kolistin

Abstract

Recently, antibiotic resistance has become an important risk threatening human and animal health. Multiple antibiotic drug resistance is frequently reported by researchers. An important topic on antibiotic resistance is Extended Spectrum Beta-lactamases, and the ESBL group consists of microorganisms that show multiple antibiotic resistance. ESBL positive bacteria are also present in animals and can infect humans through food. Therefore, the issue of ESBL is a common subject of both human and veterinary medicine. ESBL is followed closely by the scientific world and still continues its classification and species analysis studies. Therefore, the World Health Organization recommends regular follow-up of microorganisms that develop multiple antibiotic resistance, and ESBL screening and verification methods can be performed with various analyzes. Antibiotics containing carbapenems are reported as an important group used in human medicine, and resistance to carbapenem group antibiotics used against ESBL positive bacteria is increasing day by day. However, antibiotic resistance in the carbapenem group used against ESBL is life-threatening, especially in patients in intensive care. Colistin is known as the last resort antibiotic and used in combination then once again the focus of attention in the scientific world with these developments. The aim of this study is to reveal the importance of ESBL, carbapenems, and colistin antibiotic groups and the resistance developing against these antibiotic groups.

Özet

Son yıllarda antibiyotik dirençliliği insan ve hayvan sağlığını tehdit eden önemli bir risk halini almaktadır. Özellikle çoklu antibiyotik dirençlilik durumu araştırmacılar tarafından sıklıkla bildirilmektedir. Antibiyotik dirençliliği konusundaki önemli bir başlık Genişlemiş Spektrumlu Beta-laktamazlar olup, GSBL grubu çoklu antibiyotik direnci gösteren mikroorganizmalardan oluşmaktadır. GSBL pozitif bakteriler hayvanlarda da mevcut olup gıda aracılığıyla insanları enfekte edebilmektedir. Bu nedenle GSBL konusu hem beşeri tıp hem de veteriner tıbbının ortak konusudur. GSBL bilim dünyası tarafından yakından takip edilmekte ve halen GSBL’nin sınıflandırılması ve tür analiz çalışmaları devam etmektedir. Nitekim, Dünya Sağlık Örgütü çoklu antibiyotik direnç geliştiren mikroorganizmaların düzenli takip edilmesini önermekte olup, GSBL tarama ve doğrulama yöntemleri çeşitli analizler ile yapılabilmektedir. Karbapenem içeren antibiyotikler beşeri hekimlikte kullanılan önemli bir grup olarak bildirilmekte olup, GSBL pozitif bakterilere karşı kullanılan karbapenem grubu antibiyotiklere olan direnç günden güne artış göstermektedir. Bununla birlikte, GSBL’ye karşı kullanılan karbapenem grubundaki antibiyotik direnci özellikle yoğun bakımdaki hastalarda hayati tehlikeye neden olmaktadır. Son çare antibiyotiği olarak bilinen ve kombine bir şekilde kullanılan kolistin, bu gelişmeler ile tekrardan bilim dünyasında ilgi odağı olmaktadır. Bu çalışmanın amacı, ESBL, karbapenem ve kolistin antibiyotik grupları ve bu antibiyotik gruplarına karşı gelişen direncin önemini ortaya koymaktır.

🔖

Cite This Article

SÜLEYMANOĞLU, A. A., AKSU, H., AYDIN, A. (2022). Extendend Spectrum Beta-Lactamase with Carbapenem and Colsitin Resistance on Enterobacteriaceae Strains. Bozok Veterinary Sciences, Cilt: 3 - Sayı: 1, 12–19. https://ajindex.com/articles/850663

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Topçu AW, Söyletir G, Doganay M. Enfeksiyon Hastalıkları ve Mikrobiyolojisi. Nobel Tıp Kitabevleri, İstanbul, 2008; 3: 2126-2135
  2. Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, et al. Carbapenems Versus PiperacillinTazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended- Spectrum Beta-Lactamase– Producing Enterobacteriaceae. Infection Control Hospital Epidemiology 2015; 36: 981-5. doi: 10.1017/ice.2015.101
  3. Newly Reported Gene, mcr-1, Threatens Last-Resort Antibiotics. CDC 2016, https://www.cdc.gov/drugresistance/solutions-initiative/stories/gene-reported-mcr.html#:~:text=The%20gene%20has%20the%20potential,because%20of%20its%20side%20effects, Erişim: 10. 2. 2022
  4. Murray RP, Rosenthal KS, Pfaller AM. Enterobacteriaceae in Bacteriology. Medical Microbiology 2009; 25: 257-270
  5. Centers for Disease Control and Prevention (CDC), Laboratory protocol for detection of carbapenem-resistant or carbapenemase producing, Klebsiella spp. and E. coli from rectal swabs, http://www.cdc.gov/hai/pdfs/labsettings/ klebsiella_or_ecoli.pdf. 2011
  6. Health Protection Agency (HPA), Advice on carbapenemase producers: recognition, infection control and treatment. www.hpa.org.uk; 2011
  7. European Committee on Antimicrobial Susceptibility Testing (EUCAST), EUCAST breakpoint tables for interpretation of MICs and zone diameters 2011
  8. Ustaçelebi Ş. Temel ve Klinik Mikrobiyoloji. Güneş Kitapevi, Ankara, 1999; 509-511
  9. Lukac PJ, Bonomo RA, Logan LK. Extended-Spectrum -LactamaseProducing Enterobacteriaceae in Children: Old Foe, Emerging Threat. Clinical Infectious Diseases 2015; 60: 1389–1397. doi.org/10.1093/cid/civ020
  10. Forster CS, Courter J, Jackson EC, Mortensen JE, Haslam DB, Frequency of Multidrug-Resistant Organisms Cultured From Urine of Children Undergoing Clean Intermittent Catheterization. J Pediatric Infectious Diseases Society 2016; 6: 20. doi.org/10.1093/jpids/piw056
  11. Murray BE, Anderson K, Arnold K, Barlett J, Carpenter C, Erratum. Clinical Infectious Diseases 2005; 41: 279. doi.org/10.1086/430468
  12. Gür D. Beta-laktamazlar. Flora Dergisi 1997; 2: 3-18
  13. Pitout JDD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriacea: an emerging public health concern. The Lancet Infectious Diseases 2008; 8: 159-166. doi: 10.1016/S1473-3099(08)70041-0
  14. Ramphal R, Ambrose GP. Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data, Clinical Infectious Diseases, 2006; 42: 164–172, https://d